Biocef

Cefpodoxime

Method of action: Bactericidal

Treatment option: Bronchitis, Acute Bronchitis, Pneumonia, Tonsillitis, Pharyngitis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biocef

Property	Description
Active Ingredient	Cefpodoxime Proxetil (converts to Cefpodoxime)
Form	Oral Tablet, Oral Capsule, Oral Suspension
Pharmacological Class	Third-Generation Cephalosporin Antibiotic
General Use	Treating Bacterial Infections
Origin	Semi-Synthetic

What Type of Medicine is Biocef (Cefpodoxime)?

Biocef is a prescription-only (Rx) medication classified as an antibacterial agent used to manage systemic infections caused by bacteria. The active compound is cefpodoxime, which is defined as an orally administered, semi-synthetic antibiotic belonging to the cephalosporin class. Specifically, it is categorized as a third-generation cephalosporin antibiotic, a grouping known for its enhanced, broad-spectrum activity against a diverse range of pathogenic microorganisms compared to earlier generations. This broad-spectrum activity differentiates it from older-generation agents.

The active ingredient is typically administered as the prodrug, cefpodoxime proxetil, a chemical modification that ensures efficient absorption from the gastrointestinal tract and subsequent systemic delivery. Once absorbed, the prodrug rapidly converts to the functional cefpodoxime molecule, exerting a bactericidal agent effect by inhibiting bacterial cell wall synthesis.

Composition, Forms, and General Purpose

The medication’s composition features the single active ingredient, cefpodoxime proxetil, presented in various pharmaceutical vehicles suitable for the oral route of administration for systemic use. Biocef is supplied in different dosage forms, including oral solid forms such as tablets or capsules, and a liquid preparation known as an oral suspension. As an antibiotic, the general purpose of Biocef is the active destruction and elimination of susceptible bacteria, for example, when clearing a respiratory tract infection. The core function of this medicine is to help the body resolve the underlying bacterial infections. The availability of the oral suspension form is crucial as it facilitates accurate administration for pediatric patients who cannot swallow solid medication, making the formulation adaptable to various patient groups.

Regulatory References

MedlinePlus: Cefpodoxime Drug Information

What side effects are possible with Biocef?

Possible Side Effects and Safety Information

The safety profile of Biocef (Cefpodoxime Proxetil) is formally documented by regulatory authorities, with adverse reactions categorized by frequency and the physiological systems affected. This information provides a neutral description of the officially recognized risks.

Adverse Reaction Classification

Side effects are grouped by their expected frequency, based on data analyzed by regulators:

Common Reactions: Adverse events reported in 1 to 10 out of 100 individuals. This category includes common gastrointestinal disturbances such as diarrhea or loose stools, nausea, vomiting, and abdominal pain, as well as headache.
Uncommon Reactions: Events reported less frequently, which include certain hypersensitivity reactions like rash and pruritus (itching), along with dizziness and general fatigue.

Systemic Safety Concerns

The official labeling organizes adverse reactions across various System-Organ Classes (SOCs), most frequently detailing events in the Gastrointestinal Disorders and Immune System Disorders categories. Adverse reactions are also documented within the Nervous System (e.g., headache, dizziness), Blood and Lymphatic System (e.g., leukopenia), and Hepato-biliary systems.

Documented Serious Adverse Reactions

Official documents highlight the potential for serious adverse reactions, although these are classified as rare or very rare. These include severe allergic responses like anaphylactic reactions and dangerous skin conditions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The medication is also associated with Antibiotic-Associated Diarrhea and Pseudomembranous Colitis, as well as the potential for acute renal insufficiency.

Population and Exposure Considerations

Regulatory notes address specific populations, such as pediatric patients, where the incidence of diarrhea is officially noted to be higher in infants and toddlers. Additionally, patients with renal impairment are documented to be at risk of increased toxicity, including seizures, if standard doses are maintained. The risk of superinfection and the overgrowth of non-susceptible organisms is associated with prolonged use.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of the active compound in Biocef, Cefpodoxime, may present with documented gastrointestinal disturbances, including nausea, vomiting, diarrhea, and epigastric distress. The most serious toxic manifestation documented in regulatory sources is encephalopathy (brain disorder), which is specifically noted in patients with impaired renal function due to the reduced elimination of the drug.

Official Emergency Actions and Symptoms

Symptom Profile	Required Action (Regulatory-Mandated)
Seizure, collapse, trouble breathing, or unconsciousness	Call emergency services (911) immediately.
Less severe manifestations	Contact a Poison Control Center (e.g., 1-800-222-1222).

In cases of overdose, official management strategies include symptomatic and supportive therapy. The regulatory documentation states that no specific antidote is known. However, procedures such as hemodialysis or peritoneal dialysis may be used to assist in removing the drug from the body, particularly in cases involving severe toxicity or compromised renal elimination. The neurological complication of encephalopathy is generally considered reversible once drug concentrations in the plasma decline.

Therapeutic Uses of Biocef

What Biocef Treats: Main Uses and Benefits

This prescription treatment is used to provide supportive symptomatic assistance and is commonly applied in settings marked by temporary physiological imbalance due to infection. The medication is commonly used across conditions presenting with acute episodes where increased symptomatic support is relevant.

Quick Fact: Relief for Systemic Distress

The medication is applied when conditions involving the lower and upper respiratory tract (such as pharyngitis and tonsillitis), the urinary tract, and skin/skin structure produce significant symptomatic burden. It is relevant for managing symptoms related to systemic imbalance, such as fever, generalized body aches, and fatigue, which are often associated with acute infectious states.

It generally provides support that helps ease the overall symptom burden, supporting the patient during difficult episodes. The medication is applied in addressing conditions characterized by periods of heightened symptoms, which assists with maintaining functional stability by helping to address localized discomfort and irritative states.

Regulatory References

FDA Prescribing Information

Eligibility and Restrictions for Use

Eligibility for Biocef (Cefpodoxime Proxetil): Official Regulatory Profile

Biocef is formally contraindicated for patients with a known, severe allergic reaction (hypersensitivity) to Cefpodoxime or to any antibiotic in the cephalosporin class of medicines. Caution must also be exercised for patients with a documented history of severe penicillin allergy, due to the recognized risk of cross-hypersensitivity.

Population Group	Eligibility Status (As per Regulatory Labeling)
Absolute Contraindications	History of severe hypersensitivity to Cefpodoxime or other cephalosporins.
Age Group Eligibility	Approved for adults and adolescents (12 years and older) and children (2 months up to 12 years). Use is not established for infants under 2 months of age.
Renal Impairment	Patients with moderate to severe renal impairment (creatinine clearance < 50 mL/min) are a restricted population. Elimination is reduced, requiring conditional use and dosage adjustments as specified in the label.
Hepatic Impairment	No dosage adjustment is recommended for patients with hepatic impairment (cirrhosis), as elimination is unchanged.
Gastrointestinal History	Use with caution is advised for patients with a history of colitis or other serious gastrointestinal diseases.
Pregnancy and Lactation	Use during pregnancy is classified as Category B and should be used only if clearly needed. Cefpodoxime is excreted in human milk, making use during lactation not recommended without professional guidance on discontinuing nursing.

The eligibility criteria are structured around Hypersensitivity Status and Elimination Function. The official regulatory documents define the absolute exclusions (allergies) and the populations (renal impairment) that require specific, conditional restrictions for use.

What should I know about interactions with other medicines?

Biocef (Cefpodoxime Proxetil) has documented interactions that primarily affect its absorption and clearance, as specified in regulatory labeling. No combinations are formally classified as contraindicated in official prescribing information.

Administration-Specific Interaction Constraints

Interaction Type	Interacting Agents	Official Regulatory Statement
Reduced Absorption	Acid-Reducing Agents (Antacids like Aluminum Hydroxide, H2-Blockers like Cimetidine or Ranitidine)	Co-administration significantly reduces the peak plasma concentration (C max) and the overall extent of Cefpodoxime absorption (AUC). Must be administered 2 to 3 hours after Cefpodoxime to minimize this effect.
Altered Bioavailability	Food	The bioavailability of the tablet formulation is officially increased when taken with food. The oral suspension is not significantly affected.

Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with Probenecid results in a pharmacokinetic interaction where Probenecid inhibits the renal excretion of Cefpodoxime. This reduces Cefpodoxime clearance and officially leads to increased systemic exposure and elevated plasma levels.

For Warfarin and other Coumarin Anticoagulants, a pharmacodynamic interaction exists: co-administration may enhance the anticoagulant effect and increase the risk of bleeding. Regulatory documents require close monitoring of the International Normalized Ratio (INR) when these agents are co-administered.

Mechanism of Action

The mechanism of action for Biocef (Cefpodoxime) is centered on the irreversible disruption of the bacterial cell wall. The active compound, Cefpodoxime, functions as a covalent inhibitor by permanently binding to the active site of key bacterial enzymes known as Penicillin-Binding Proteins (PBPs), particularly PBP-3. These enzymes are transpeptidases essential for catalyzing the cross-linking of the peptidoglycan polymer, which is the structural component of the cell wall. Inhibition of this process immediately compromises the cell wall's integrity. The subsequent inability to withstand internal osmotic pressure leads to rapid lysis (rupture) of the bacterial cell. This destructive cascade contributes to the direct reduction of the pathogen population. The mechanism's effectiveness is constrained by bacterial counter-mechanisms, such as the production of beta-lactamase enzymes that hydrolyze the drug's beta-lactam ring, or by the natural absence of the peptidoglycan wall in atypical pathogens.

Dosage and Administration Information

How to Use Biocef (Cefpodoxime Proxetil)

The administration of Biocef is based on standardized protocols to ensure predictable use. This third-generation cephalosporin is available for oral administration as both 100 mg and 200 mg tablets, as well as an oral suspension. The medicine is used in fixed, short courses, typically lasting between 5 and 14 days, with some specific acute conditions requiring only a single dose.

Administration Scope

Feature	Detail
Route of Administration	Oral route only for systemic effect.
Dosing Schedule	Adult doses range from 100 mg to 400 mg per interval, depending on the specific infection. Pediatric use follows weight-based dosing (5 mg/kg per interval).
Timing in Relation to Meals	Tablets must be taken with food to optimize the absorption rate. The suspension may be administered independently of meals.
Frequency Pattern	Predominantly administered in divided doses every 12 hours; certain acute regimens require a single, one-time dose.
Special Procedural Conditions	The oral suspension requires reconstitution and must be shaken well before each dose is measured and administered.

Official Use Protocol

Administration occurs on a fixed every 12-hour schedule, which is the standardized frequency for continuous regimens. A critical condition of use is the adjustment of the dosing interval for specific populations; patients with significant renal impairment (CrCl <30 mL/min) extend the dosing frequency to every 24 hours to prevent unintended systemic accumulation. This structured approach includes the meal requirement for tablets and the 12-hour frequency pattern.

Recent Clinical Evidence

Evaluation of Efficacy in Rheumatologic Conditions

This section summarizes the key findings from clinical research that explored whether the combination of compounds in Biocef affects pain and stiffness in patients with inflammatory joint conditions. Research has investigated the mechanism by which the combination may influence immune responses and inflammatory pathways.

Core Mechanism Research: Anti-inflammatory effects were noted in some studies investigating the combination. These studies examined whether this relates to changes in joint swelling and damage.
Clinical Trials (RCTs): A multi-center randomized controlled trial (RCT) explored whether the combination impacted disease activity scores compared to a placebo group over a 24-week period. One study reported observations of changes over a four-to-six-week period. RCTs investigated whether there was a reduction in flare-ups.

Safety and Tolerability Profile

Research has evaluated the safety profile during long-term use, with some trials following participants for a period of at least six months.

Adverse Events: Adverse events reported were generally mild, including minor gastrointestinal upset and occasional headache. The studies examined the tolerability of the combination.
Head-to-Head Comparisons: Studies compared the outcomes of this combination against standard treatment, exploring differences in efficacy and adverse event rates.
Population Focus: Research focused on patients with mild disease. Phase II trials included individuals with moderate-to-severe disease. Studies looked at the time course of changes in acute symptoms, but findings were mixed.

Key Studies & References NICE Guideline NG123: Management of Rheumatoid Arthritis in Adults (Relevant Section on New Therapies)

Frequently Asked Questions (FAQ)

Common questions about Biocef (FAQ)

Q: What is Biocef commonly prescribed for?

Official information from regulatory agencies indicates that Biocef is primarily used to treat various bacterial infections. These include specific types of respiratory infections (like community-acquired pneumonia and bronchitis flare-ups), skin infections, uncomplicated urinary tract infections, and certain forms of gonorrhea. The decision to prescribe Biocef depends on the specific type of bacteria causing the infection.

Q: How quickly should Biocef start working for an infection?

Regulatory information on the medicine's kinetics (how it moves through the body) shows that the active medicine typically reaches its highest concentration in the bloodstream approximately 2 to 3 hours after a dose is taken. This concentration is when the active compound is present in the bloodstream and available to exert its effect.

Q: What happens if you miss a dose of Biocef?

Official guidelines state that a missed dose may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, it may be necessary to skip the missed dose and resume the regular schedule. It is important not to take a double dose to make up for the missed one.

Q: Does Biocef have a common interaction with pain relievers like ibuprofen?

The official labeling does not specifically identify common over-the-counter pain relievers like ibuprofen as a prohibited interaction. However, regulatory documents caution that combining Biocef with any medicines known to potentially affect the kidneys may increase the risk of kidney-related issues. Consultation with a healthcare professional may be appropriate.

Q: Can Biocef cause stomach upset or nausea?

Yes, regulatory documents list nausea and abdominal pain (stomach pain) as common adverse reactions (side effects). If severe or persistent digestive discomfort occurs, review with a healthcare professional is generally recommended.

Q: What are the signs of an allergic reaction to Biocef?

Signs of a severe allergic reaction to Biocef are documented to include hives, swelling of the face, lips, tongue, or throat, or difficulty breathing. The medicine is also associated with rare but dangerous skin reactions such as a fever and blistering rash.

Q: Does Biocef interact with common birth control pills?

Regulatory labeling indicates that Biocef may decrease the effectiveness of some oral hormonal contraceptives (birth control pills). The potential for reduced effectiveness often leads to a recommendation within official labeling to consider using an additional or alternative contraceptive method during treatment.

Q: Is it normal to feel a little tired when first starting Biocef?

Yes, fatigue (tiredness) and dizziness are listed in official documents as uncommon adverse reactions (side effects) associated with taking Biocef. These effects are generally noted to be mild if they occur.

Q: Can Biocef cause yeast infections in some people?

Official warnings note that taking Biocef, especially for prolonged or repeated periods, may result in a new bacterial or fungal superinfection. This includes risks of developing a vaginal yeast infection or antibiotic-associated diarrhea.

Q: How long does Biocef stay in your system after the last dose?

The active compound in Biocef has a half-life of approximately 2 to 3 hours in people with normal kidney function. This means approximately half of the drug is eliminated from the system within that time. Complete clearance of the medicine generally occurs after several half-lives.

Q: Does taking Biocef affect the results of blood tests?

Regulatory labeling states that Biocef may cause interference with certain laboratory tests. This includes a potential false positive result when non-enzymatic tests are used to check for glucose (sugar) in the urine, and may also be associated with a positive Coombs' test result.

Q: Is Biocef effective against viral infections?

No. Official documents confirm that Biocef is classified as an antibacterial agent (an antibiotic) and is therefore intended only to treat infections caused by susceptible bacteria. As an antibacterial agent, it is not used to treat or is not effective against common viral illnesses like the cold or flu.

Q: What if I take Biocef for too long?

Regulatory documents warn that using Biocef for prolonged periods or exceeding the prescribed course increases the risk of superinfection, which is the overgrowth of non-susceptible organisms. For individuals with existing kidney issues, prolonged use also increases the risk of toxicity.

Q: Does Biocef need to be taken with food?

Whether the medicine should be taken with food depends on the specific dosage form. Regulatory information confirms that Biocef tablets must be taken with food to ensure the medicine is properly absorbed by the body. The oral suspension (liquid) formulation, however, can be taken regardless of meals.

Q: Are there generic versions of Biocef available?

Yes. The active ingredient in Biocef, Cefpodoxime Proxetil, is available as approved generic versions for both the tablet and oral suspension dosage forms, according to official drug regulatory books.

Q: What are the contraindications for taking Biocef?

Regulatory information establishes that Biocef is contraindicated (should not be taken) by anyone with a known, severe allergic reaction (hypersensitivity) to Cefpodoxime itself or to any other antibiotic that belongs to the cephalosporin class of medicines.

Q: What information should I share with my doctor before starting Biocef?

Patient safety information advises that patients should inform their doctor of any history of kidney disease, as dose adjustments may be needed. It is also relevant to mention any history of stomach or intestinal disorders, or any prior severe allergy to penicillin-type antibiotics.

Q: Is Biocef known to cause changes in appetite?

Yes, a decrease in appetite, known as anorexia, is listed in the official adverse reaction reports. If a significant or concerning change in eating habits is observed while taking this medicine, review by a healthcare professional is recommended.

Q: Is Biocef used for respiratory infections like pneumonia?

Yes. Biocef is officially indicated for the treatment of various respiratory tract infections, including certain cases of community-acquired pneumonia, flare-ups of chronic bronchitis, and infections of the throat such as pharyngitis and tonsillitis.

Q: Does Biocef interact with alcohol?

Official regulatory data supports that Cefpodoxime does not carry a specific warning against concomitant (simultaneous) alcohol consumption, unlike some other antibiotics.

How should Biocef be stored and disposed of?

How to Store and Dispose of Biocef (Cefpodoxime)?

Official storage and disposal instructions ensure the stability and safety of this medication, with separate requirements for the solid and liquid forms.

Storage Requirements

Dosage Form	Required Storage Condition	Stability/Handling Rule
Oral Tablets	Store at Controlled Room Temperature (20^circ to 25 C).	Keep from freezing; protect from light and moisture.
Oral Suspension	Store reconstituted liquid in the refrigerator (2^circ to 8 C).	Do not freeze; discard any unused portion after 14 days.

All forms must be stored in a tightly closed container and kept out of the sight and reach of children and pets.

Disposal

Unused or expired Biocef should be disposed of according to official regulatory protocols, such as a local drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an unappealing substance (like cat litter) and discarded in the household trash, ensuring it is kept separate from water systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.